GRAIL
GRAIL Innovation & Technology Culture
GRAIL Employee Perspectives
What types of products or services does your engineering team work on/create? What problem are you solving for customers?
My team works mostly on internal applications, making it easier for various roles to access and modify production data. I also make developer tools. These days, I mostly work on things I identify as having value, whether it’s a front-end engineer, someone in marketing or research. I am passionate about creating.
Tell us about a recent project where your team used AI as a tool. What was it meant to accomplish? How did you use AI to assist?
In the past month, I’ve built new production-grade prototypes for the following: a template management app; an integrated Optical Character Recognition tool; some AI-assistant coding tools; a robust mock-data generation tool; and an automated workflow generation tool. I’ve added command line interfaces for everything I’ve touched. I’ve also been expanding features on existing operations apps. All these things were built with AI, and some of them have AI in their function. I added most of a complex feature to an existing app on Friday alone. I am personally more than 10 times as fast as I was a year ago.
What would that project have looked like if you didn’t have AI as a tool to use? How has AI changed the way you work, in general?
I maybe would have built two of those things, and neither would be nearly as good as it has become already. A number of these projects I would not have even attempted before AI.
What People Are Saying About GRAIL
-
Product Innovation: The Galleri test applies targeted cfDNA methylation sequencing with machine‑learning to detect a common cancer signal and predict likely tissue of origin from a single blood draw, achieving very high specificity in studies. Its breadth across dozens of cancers and accurate guidance for diagnostic workups differentiate it from organ‑specific screens.
-
Investment in R&D: The company executed multi‑year, multi‑study programs (e.g., CCGA, PATHFINDER/2, SYMPLIFY) and uniquely partnered with NHS England for a national‑scale randomized controlled trial—evidence generation uncommon in diagnostics. Real‑world efforts in Medicare‑aged populations and integrations with large health systems reinforce continued investment.
-
Innovation Leadership: The firm helped define the MCED category and advanced it to regulatory milestones with FDA Breakthrough Device designation and a PMA submission in early 2026. Health‑system integrations and health‑system–scale trials position the technology within routine care pathways.
GRAIL's Tech Stack
